Protocol Ledger

NCT05055128 · Phase II · COMPLETED

A Study in Patients With Erosive Esophagitis to Investigate Safety, Tolerability, and Healing Rates After 4 Weeks Treatment of X842 or Lansoprazole and Symptom Pattern During Subsequent 4 Weeks Treatment With Lansoprazol

Interventional Phase II clinical trial protocol NCT05055128 sponsored by Cinclus Pharma Holding in Rare Genetic, Women's Health, and Other, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2021-08-11 Enrollment: 248 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT05055128
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)248 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)0 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT05055128
Protocol FieldVerified Registry Value
NCT IdentifierNCT05055128
Consolidated Lead SponsorCinclus Pharma Holding
Therapeutic Condition CohortRare Genetic, Women's Health, and Other
Clinical Trial PhasePhase II
Overall Recruitment StatusCOMPLETED
Registered Enrollment248 participants (ACTUAL)
Registered Start Date2021-08-11
WhyStopped ClassificationNot Stopped

Search related sites and sponsors in the Interactive Directory, explore Rare Genetic, Women's Health, and Other Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI